The Food and Drug Administration (FDA) has approved Zynyz ® (retifanlimab-dlwr), in combination with carboplatin and paclitaxel, for the first-line treatment ... with locally advanced or ...

evaluates the efficacy and safety of LBL-024 combined with etoposide plus platinum-based chemotherapy as a first-line treatment for advanced EP-NEC. As of April 15th, 2025, with a median follow-up ...

evaluates the efficacy and safety of LBL-024 combined with etoposide plus platinum-based chemotherapy as a first-line treatment for advanced EP-NEC. Dr. Xiaoqiang Kang, Founder, Chairman and CEO ...

evaluates the efficacy and safety of LBL-024 combined with etoposide plus platinum-based chemotherapy as a first-line treatment for advanced EP-NEC. Dr. Xiaoqiang Kang, Founder, Chairman and CEO of ...

Republican deficit hawks allowed President Trump’s bill of legislative priorities to advance out of the House ... The four hard-line conservatives who tanked the vote on the legislation Friday ...

Zynyz ® (retifanlimab-dlwr), a PD-1 inhibitor, is now approved for the treatment of advanced squamous cell carcinoma of the anal canal (SCAC) in combination with chemotherapy and as a monotherapy ...